drugset / Trial / NCT06097676
An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users
RandomizedCrossoverQuadruple-blindOther
Summary
The purpose of this study is to assess the abuse potential of gabapentin enacarbil in healthy adult, non-dependent, recreational drug users.
Timeline
- Start
- 2021-09-28
- Primary completion
- 2022-06-30
- Completion
- 2022-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Alprazolam | Small molecule | 2 mg | Oral |
| Subject | gabapentin enacarbil | Small molecule | 200 mg | Oral |
| Subject | gabapentin enacarbil | Small molecule | 450 mg | Oral |
| Subject | gabapentin enacarbil | Small molecule | 700 mg | Oral |